Bio Medica Laboratories IPO
Bio Medica Laboratories IPO Details
-
Open Date
21 May 2026
-
Close Date
25 May 2026
- IPO Price Range
₹ 132 to ₹139
- IPO Size
₹ 52.43 Cr
Bio Medica Laboratories IPO Timeline
Bio Medica Laboratories IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 21-May-2026 | 15.94 | 0.03 | 1.09 | 0.72 |
| 22-May-2026 | 15.94 | 0.01 | 1.20 | 0.76 |
Last Updated: 22 May 2026 10:40 AM by 5paisa
Bio Medica Laboratories specialises in the manufacture of pharmaceutical parenteral formulations, offering a broad portfolio of ethical medicines, generic drugs and over-the-counter (OTC) products in liquid and dry-powder injectable forms for both human and veterinary healthcare. The company provides 58 liquid injectables and 15 dry-powder injectables in single-dose and multi-dose formats. Operating exclusively on a B2B contract manufacturing model, it develops customised formulations to client specifications and holds GMP and GLP certifications issued by the Food & Drugs Administration, Madhya Pradesh.
Established in: 2015
Managing Director: Mr. Pradeep Mehta.
Peers:
Zenotech Laboratories Limited
Shukra Pharmaceuticals Limited
Bio Medica Laboratories Objectives
1. Repayment of loan (₹6.50 Cr)
2. Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (₹28.50 Cr)
3. General Corporate Purposes
Bio Medica Laboratories IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹52.43 Cr |
| Offer For Sale | ₹5.24 Cr |
| Fresh Issue | ₹47.19 Cr |
Bio Medica Laboratories IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | 2,64,000 |
| Retail (Max) | 2 | 2,000 | 2,78,000 |
| S-HNI (Min) | 3 | 3,000 | 3,96,000 |
| S-HNI (Max) | 7 | 7,000 | 9,73,000 |
| B-HNI (Min) | 8 | 8,000 | 10,56,000 |
Bio Medica Laboratories IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 15.94 | 36,000 | 5,74,000 | 7.979 |
| Non-Institutional Buyers | 0.01 | 17,55,000 | 9,000 | 0.125 |
| BNII | 0.02 | 11,70,000 | 24,000 | 0.334 |
| SNII | 0.30 | 5,85,000 | 1,74,000 | 2.419 |
| Individual Investors (IND category bidding for 2 Lots) | 1.20 | 17,92,000 | 21,46,000 | 29.829 |
| Total** | 0.76 | 35,83,000 | 27,29,000 | 37.933 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 16.23 | 15.25 | 38.20 |
| EBITDA | 1.70 | 5.63 | 15.21 |
| PAT | 0.33 | 2.50 | 9.79 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 17.57 | 19.53 | 39.12 |
| Share Capital | 0.10 | 0.10 | 9.18 |
| Total Liabilities | 10.19 | 6.56 | 16.99 |
| Cash Flows (₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | - | - | - |
| Net Cash Generated From / (used in) Investing Activities | -1.69 | -1.54 | 0.34 |
| Net Cash Generated From / (used in) Financing Activities | -2.13 | -0.08 | 3.33 |
| Net Increase (Decrease) in Cash and Cash Equivalents | -1.52 | 0.04 | -0.04 |
Strengths
1. Strong expertise in pharmaceutical injectable formulation manufacturing
2. Diverse portfolio across liquid and powder injectables
3. GMP and GLP certifications ensure quality compliance
4. Specialised B2B contract manufacturing business model focus
Weaknesses
1. Heavy dependence on third-party contract manufacturing clients
2. Limited presence in branded consumer pharmaceutical markets
3. Product portfolio concentrated mainly in injectable formulations
4. Regulatory compliance costs may impact profitability margins
Opportunities
1. Growing demand for injectable pharmaceuticals across healthcare sectors
2. Expansion into international regulated pharmaceutical export markets
3. Rising veterinary healthcare demand supports product diversification
4. Increasing outsourcing trends among pharmaceutical manufacturing companies
Threats
1. Intense competition from established pharmaceutical manufacturing companies
2. Strict regulatory changes affecting pharmaceutical production operations
3. Raw material price volatility impacting manufacturing cost structures
4. Client dependency risks from contract termination or losses
1. Strong injectable manufacturing expertise with diversified product portfolio
2. Growing pharmaceutical outsourcing trends support business expansion opportunities
3. Certified GMP and GLP facilities ensure regulatory compliance
4. Exclusive B2B model provides stable long-term client relationships
Bio Medica Laboratories operates within the growing pharmaceutical injectable manufacturing sector, supported by increasing healthcare expenditure, rising demand for generic medicines and expanding veterinary healthcare needs. Its specialised focus on liquid and dry-powder injectables positions the company favourably in the contract manufacturing market. With GMP and GLP certifications, the company is well-placed to strengthen client relationships, expand production capabilities and explore export opportunities in regulated international pharmaceutical markets, supporting long-term business growth potential.
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Bio Medica Laboratories IPO opens from May 21, 2026 to May 25, 2026.
The size of Bio Medica Laboratories IPO is ₹52.43 Cr.
The price band of Bio Medica Laboratories IPO is fixed at ₹132 to ₹139 per share.
To apply for Bio Medica Laboratories IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Bio Medica Laboratories. IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Bio Medica Laboratories IPO is of 2,000 shares and the investment required is ₹2,64,000.
The share allotment date of Bio Medica Laboratories IPO is May 26,2026
The Bio Medica Laboratories IPO will likely be listed on May 29, 2026.
Narnolia Financial Services Ltd is the book running lead managers for Bio Medica Laboratories IPO.
Bio Medica Laboratories IPO plans to utilise the raised capital from the IPO for:
1. Repayment of loan (₹6.50 Cr)
2. Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (₹28.50 Cr)
3. General Corporate Purposes